Skip to main content
Boston ScientificNews

Boston Scientific anticipates a difficult 2027 due to pricing policy in China and weakness

Source: Autobound Signal API · 115 signals tracked for Boston Scientific · updated

Get Boston Scientific's live signals in Claude or ChatGPT, or by API

AskWhat changed at Boston Scientific this week? Use Autobound signals for bostonscientific.com.

What happened

Boston Scientific expects to finalize the acquisition of Penumbra, valued at $14.5 billion, in the first quarter of 2027.

Source

Article excerpt

(Automatic translation by Reuters using machine learning and generative AI, please refer to the following disclaimer: https://bit.ly/rtrsauto) by Padmanabhan Ananthan Boston Scientific BSX.N on Wednesday lowered its full-year profit forecast and warned that revenue and profit growth could prove difficult in 2027, citing pricing pressures in China and weakness in its core cardiac device business. The company's shares fell 5.3% in late afternoon trading. “We anticipate continued top-line pressure extending through 2027, which we believe will make it challenging to grow revenue and adjusted earnings per share,” said Chief Financial Officer Jon Monson on a conference call. The medical technology company now expects an adjusted profit for 2026 of between $3.16 and $3.18, compared to a previous range of $3.28 to $3.32. According to data compiled by LSEG, analysts are expecting an average profit of $3.23 per share. The company expects a fourth-quarter revenue decline of approximately 3% to 1% year-over-year, as well as an adjusted profit between 77 cents and 79 cents per share, which is below the analysts' estimate of 83 cents per share. Chief Executive Officer Mike Mahoney said: “There will be additional pricing headwinds in China in 2027, and growth is likely not going to be sufficient to offset the pressure from electrophysiology and Watchman next year.” Farapulse and Watchman...

Keep reading with a free account

The rest of this article, and every signal for Boston Scientific, is in your free account.

Extracted from this sentence

Boston Scientific now expects to finalize the acquisition of Penumbra, valued at $14.5 billion, in the first quarter of 2027, later than initially planned due to longer regulatory review procedures.

Extracted by Autobound

From the Signal API record
Event
News

What this signalsIntegration work after a deal often opens needs for new systems and services.

Amount named
$14.5B

Companies

  • PenumbraTargetpenumbrainc.com

The full record

From the Signal API record

Numbers

Amount named in the story
$14.5B

Extraction

Confidence
95%
Detected
Oct 28, 2026
signal_type
news
signal_subtype
acquires

Use this data

Get every news signal for Boston Scientific and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Boston Scientific this week?”

  2. Send it to your own tools

    The Signal API returns news signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/cb12837d-5711-e8a8-eb14-16127acbacc5 returns this record as JSON. POST /v1/companies/enrich returns every signal for bostonscientific.com.

{
  "signal_id": "cb12837d-5711-e8a8-eb14-16127acbacc5",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-10-28T16:47:46+00:00",
  "company": {
    "name": "Boston Scientific",
    "domain": "bostonscientific.com"
  },
  "data": {
    "url": "https://www.boursorama.com/bourse/actualites-amp/boston-scientific-prevoit-une-annee-2027-difficile-en-raison-de-la-politique-tarifaire-en-chine-et-de-la-faiblesse-du-marche-des-dispositifs-cardiaques-12a03ab11d0e189886fe1fb8d8c02520",
    "title": "Boston Scientific anticipates a difficult 2027 due to pricing policy in China and weakness - Boursorama",
    "excerpt": "(Automatic translation by Reuters using machine learning and generative AI, please refer to the following disclaimer: https://bit.ly/rtrsauto) by Padmanabhan Ananthan Boston Scientific BSX.N on Wednesday lowered its full-year profit forecast and warned that revenue and profit growth could prove difficult in 2027, citing pricing pressures in China and weakness in its core cardiac device business. The company's shares fell 5.3% in late afternoon trading. “We anticipate continued top-line pressure extending through 2027, which we believe will make it challenging to grow revenue and adjusted earnings per share,” said Chief Financial Officer Jon Monson on a conference call. The medical technology company now expects an adjusted profit for 2026 of between $3.16 and $3.18, compared to a previous range of $3.28 to $3.32. According to data compiled by LSEG, analysts are expecting an average profit of $3.23 per share. The company expects a fourth-quarter revenue decline of approximately 3% to 1% year-over-year, as well as an adjusted profit between 77 cents and 79 cents per share, which is below the analysts' estimate of 83 cents per share. Chief Executive Officer Mike Mahoney said: “There will be additional pricing headwinds in China in 2027, and growth is likely not going to be sufficient to offset the pressure from electrophysiology and Watchman next year.” Farapulse and Watchman are...",
    "summary": "Boston Scientific expects to finalize the acquisition of Penumbra, valued at $14.5 billion, in the first quarter of 2027.",
    "planning": true,
    "image_url": "https://www.boursorama.com/bundles/boursoramaui/images/news/trading-news-0.jpg",
    "confidence": 0.95,
    "published_at": "2026-10-28T16:47:46Z",
    "article_sentence": "Boston Scientific now expects to finalize the acquisition of Penumbra, valued at $14.5 billion, in the first quarter of 2027, later than initially planned due to longer regulatory review procedures.",
    "amount_normalized": 14500000000,
    "related_company_name": "Penumbra",
    "related_company_domain": "penumbrainc.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.